

#### www.immunoway.com

# BCL-2 (PTR2303) Mouse mAb

CatalogNo: YM3041 KD/KO Validated 🔏

KD/KO Validated 🕅 Orthogonal Validated 💽

## Key Features

Host Species

Mouse

MW • 26kD (Calculated) 26kD (Observed) ReactivityHuman, Mouse, Rat,

Applications
• WB,IF,ELISA

Isotype • IgG2b,Kappa

## Recommended Dilution Ratios

WB 1:500-2000 IF 1:100-500 ELISA 1:1000-5000

## **Storage**

Storage*	-15°C to -25°C/1 year(Do not lower than -25°C)
Formulation	PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA

### **Basic Information**

Clonality	Monoclonal			
<b>Clone Number</b>	PTR2303			

## Immunogen Information

ImmunogenSynthetic Peptide of human Bcl-2 AA range: 1-100SpecificityThis antibody detects endogenous levels of BCL-2 protein.

## Target Information

BCL2		
Apoptosis regulator Bcl-2 <b>Organism</b>	Gene ID	UniProt ID
Human	<u>596;</u>	<u>P10415;</u>
Mouse	<u>12043;</u>	<u>P10417;</u>
Rat	<u>24224;</u>	<u>P49950;</u>
	Apoptosis regulator Bcl-2 <b>Organism</b> Human Mouse	OrganismGene IDHuman596;Mouse12043;

### Cellular Membranous


### Localization

**Tissue specificity** Expressed in a variety of tissues.


#### Function

Disease: A chromosomal aberration involving BCL2 may be a cause of follicular lymphoma (FL) [MIM:151430]; also known as type II chronic lymphatic leukemia. Translocation t(14;18)(q32;q21) with immunoglobulin gene regions. BCL2 mutations found in non-Hodgkin lymphomas carrying the chromosomal translocation could be attributed to the Ig somatic hypermutation mechanism resulting in nucleotide transitions., Domain: The BH4 motif is required for anti-apoptotic activity and for interaction with RAF-1., Function: Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1)., online information: Bcl-2 entry, PTM: Phosphorylation/dephosphorylation on Ser-70 regulates anti-apoptotic activity. Growth factor-stimulated phosphorylation on Ser-70 by PKC is required for the antiapoptosis activity and occurs during the G2/M phase of the cell cycle. In the absence of growth factors, BCL2 appears to be phosphorylated by other protein kinases such as ERKs and stress-activated kinases. Dephosphorylated by protein phosphatase 2A (PP2A)., PTM: Proteolytically cleaved by caspases during apoptosis. The cleaved protein, lacking the BH4 motif, has pro-apoptotic activity, causes the release of cytochrome c into the cytosol promoting further caspase activity., similarity: Belongs to the Bcl-2 family., subunit: Forms homodimers, and heterodimers with BAX, BAD, BAK and Bcl-X(L). Heterodimerization with BAX requires intact BH1 and BH2 motifs, and is necessary for antiapoptotic activity (By similarity). Also interacts with APAF1, RAF-1, TP53BP2, BBC3, BCL2L1, MRPL41 and BNIPL. Binding to FKBP8 seems to target BCL2 to the mitochondria and probably interferes with the binding of BCL2 to its targets., tissue specificity: Expressed in a variety of tissues.,

### Validation Data



Various whole cell lysates were separated by 10% SDS-PAGE, and the membrane was blotted with anti-BCL-2(PTR2303)antibody. The HRP-conjugated Goat anti-Mouse IgG(H + L) antibody was used to detect the antibody. Lane 1: THP-1 Lane 2: MOLT-4 Lane 3: Raji Lane 4: HL-60 Lane 5: K562 Lane 6: Daudi Lane 7: Raw264.7 Lane 8: Mouse spleen Lane 9: Rat thymus



Western blot analysis of lysates from 1)Hela cell , 2)Hela cells knockdown by siRNA1 (F:GGAUGACUGAGUACCUGAATT,R:UUCAGGUACUCAGUCAUCCTT) siRNA2(F:GUGAUGAAGUACAUCCAUUAU,R:AUAAUGGAUGUACUUCAUCAC), (Green) primary antibody was diluted at 1:1000, 4°over night, Dylight 800 secondary antibody(Immunoway:RS23910)was diluted at 1:10000, 37° 1hour. (Red) GAPDH rabbit (Immunoway:YN5585) antibody was diluted at 1:5000 as loading control, 4° over night, Dylight 680 secondary antibody(Immunoway:RS23720)was diluted at 1:10000, 37° 1hour.

G		AGS			MGC-803		
siScramble	+	-	-	+	-	-	
siFGFR2-1	-	+	-	-	+	-	
siFGFR2-2	-	-	+	-	-	+	
FBS stimulation	+	+	+	+	+	+	
p-FGFR (Tyr653/654, 120kD)	*	- 24	-	i-a	in.		
FGFR2 (110kD)	10	-	-	-	-	-	
p-MEK1/2 (45kD)		-	-	-	-	-	
p-ERK1/2 (42/44kD)		-	-	-	-	-	
ERK1/2 (42/44kD)	1	1		-	1	-	
Cyclin D1 (36kD)		1	-	-	-		
P21 (21kD)	-	-	•	-		-	
P27 (27kD)	-	-	-		-		
p-Rb (110kD)	-	3	-	-	80.09	Here's	
c-PARP (89kD)	****	-		-	-	-	
PARP (116kD)	-		-	-	•	-	
Bcl2 (26kD)	-	-	-		-		
β-Actin (42kD)	-	-	-	-	-	-	

D E Sham SCI Res Res+CQ CQ Bax Bcl-2 C-caspase3 GAPDH Zhang, J., Wong, C.C., Leung, K.T. et al. FGF18–FGFR2 signaling triggers the activation of c-Jun–YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential. Oncogene 39, 6647–6663 (2020).

Wang, Peng, et al. "Resveratrol ameliorates autophagic flux to promote functional recovery in rats after spinal cord injury." Oncotarget 9.9 (2018): 8427.

## **Contact information**

Orders:	order@immunoway.com
Support:	tech@immunoway.com
Telephone:	877-594-3616 (Toll Free), 408-747-0185
Website:	http://www.immunoway.com
Address:	2200 Ringwood Ave San Jose, CA 95131 USA



Please scan the QR code to access additional product information: BCL-2 (PTR2303) Mouse mAb For Research Use Only. Not for Use in Diagnostic Procedures.

Immunoway - 4 / 4